课题基金 / 基金详情

The analysis of the role and inhibition of heparanase in cancer metastasis and inflammation

The analysis of the role and inhibition of heparanase in cancer metastasis and inflammation
乙酰肝素酶在癌症转移和炎症中的作用及抑制作用分析
批准号:
13671306
负责人:
NAOMOTO Yoshio
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

NAOMOTO Yoshio的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Heparanase (Hpa) is an endo-b-D-glucuronidase that specifically cleaves carbohydrate chains of heparan sulfate proteoglycans (HSPG) s. HSPGs are distributed ubiquitously and are common constituents of cell surfaces and the ECM, including basement membranes. HSPGs also bind and sequester a variety of bioactive proteins, including growth factors, chemokines, cytokines, and enzymes. After cleaving HSPGs by Hpa, HS-binding growth factors, such as bFGF, TGF-b, PDGF and VEGF, are released and activated. Hpa is involved in embryonic morphogenesis, wound healing, tissue repair and inflammation. The enzyme has been identified in a variety of normal and malignant cells and tissues, e.g., skin fibroblasts, cytotrophoblasts, hepatocytes, endothelial cells, platelets, mast cells, neutrophils, macrophages, T and B-lymphocytes, lymphoma, melanoma, and cancer cells. Previous studies demonstrated that the expression of Hpa gene and protein correlated with metastatic potential of several human and mouse … More cell lines such as breast, bladder, prostate, melanoma and T-lymphoma. We found that heparanase had an important role in gastric cancer invasion and metastasis and in other tumors. (Uno F, Naomoto Y et al; Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res. 61(21):7855-60, 2001, Takaoka M, Naomoto Y et al; Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest. 83(5):613-22, 2003 )Heparanase has also important roles in inflammatory bowel disease and other diseases. Those results were submitted in the journals as follows ; (Nobuhisa T, Naomoto Y et al; Heparanase is a marker of poor prognosis and malignant potential of colon cancer. Submitted, in Clinical Cancer Research / Imada T, Naomoto Y et al; COX-2-induction by heparanase in the progession of breast cancer. Submitted in Cancer Research / Ohkawa T, Naomoto Y et al; Cytoplasmic, and nuclear localization of heparanase in esophageal cancer cells : Respective roles in prognosis and differentiation. Submitted in Cancer Research) Less
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Uetsuka H, et al.: "Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line"Experimental Cell Research. 289. 27-35 (2003)
Uetsuka H 等人:“抑制诱导型 NF-κB 活性可降低人胃癌细胞系对 5-氟尿嘧啶的化疗耐药性”实验细胞研究。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Functional Analysis of Heparanase-Development of Therapeutic Modalities for Antiangiogenesis and Defferentiation-
  • 批准号:
    18591464
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.52万
  • 财政年份:
    2006
  • 负责人:
    NAOMOTO Yoshio
  • 依托单位:
Inhibition of cancer invasion and metastasis targeting heparanase
  • 批准号:
    16591319
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.37万
  • 财政年份:
    2004
  • 负责人:
    NAOMOTO Yoshio
  • 依托单位:
Inhibition of cytokine production and suppression of graft rejection by macrophage colony stimulating factor.
  • 批准号:
    06671206
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 资助金额:
    $1.34万
  • 财政年份:
    1994
  • 负责人:
    NAOMOTO Yoshio
  • 依托单位:
国内基金
海外基金
TGF-β/lnc-APUE/ZEB1通路促进肝癌转移的机制及生物学意义
  • 批准号:
    32100616
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李颂扬
  • 依托单位:
乳腺癌细胞外泌体miRNA诱导组蛋白修饰表观调控巨噬细胞M2极化的机制探索
  • 批准号:
    31960152
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    39.0万元
  • 批准年份:
    2019
  • 负责人:
    罗达亚
  • 依托单位:
内质网蛋白Ei24调控胰腺癌细胞迁移、侵袭的分子机制研究
泛素连接酶TRIM65通过RhoGAP调控Rho活性促进结直肠癌侵袭转移的分子机制
  • 批准号:
    31970703
  • 项目类别:
    面上项目
  • 资助金额:
    50.0万元
  • 批准年份:
    2019
  • 负责人:
    陈代词
  • 依托单位: